ID   P5CR1_HUMAN             Reviewed;         319 AA.
AC   P32322; A6NFM2; B4DMU0; Q6FHI4; Q96DI6; Q9HBQ4;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2005, sequence version 2.
DT   10-MAY-2017, entry version 165.
DE   RecName: Full=Pyrroline-5-carboxylate reductase 1, mitochondrial;
DE            Short=P5C reductase 1;
DE            Short=P5CR 1;
DE            EC=1.5.1.2;
GN   Name=PYCR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1730675;
RA   Dougherty K.M., Brandriss M.C., Valle D.;
RT   "Cloning human pyrroline-5-carboxylate reductase cDNA by
RT   complementation in Saccharomyces cerevisiae.";
RL   J. Biol. Chem. 267:871-875(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Gu J.R., Wan D.F., Zhao X.T., Zhou X.M., Jiang H.Q., Zhang P.P.,
RA   Qin W.X., Huang Y., Qiu X.K., Qian L.F., He L.P., Li H.N., Yu Y.,
RA   Yu J., Han L.H.;
RT   "Novel Human cDNA clones with function of inhibiting cancer cell
RT   growth.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-17 AND 205-215, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [9]
RP   PROTEIN SEQUENCE OF 2-46; 130-147; 205-215 AND 252-264, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, VARIANTS ARCL2B GLY-119; HIS-119;
RP   THR-179; TRP-206 AND ARG-206, VARIANTS ARCL3B HIS-251 AND THR-257, AND
RP   VARIANT VAL-189.
RX   PubMed=19648921; DOI=10.1038/ng.413;
RA   Reversade B., Escande-Beillard N., Dimopoulou A., Fischer B.,
RA   Chng S.C., Li Y., Shboul M., Tham P.-Y., Kayserili H., Al-Gazali L.,
RA   Shahwan M., Brancati F., Lee H., O'Connor B.D., Schmidt-von Kegler M.,
RA   Merriman B., Nelson S.F., Masri A., Alkazaleh F., Guerra D.,
RA   Ferrari P., Nanda A., Rajab A., Markie D., Gray M., Nelson J.,
RA   Grix A., Sommer A., Savarirayan R., Janecke A.R., Steichen E.,
RA   Sillence D., Hausser I., Budde B., Nuernberg G., Nuernberg P.,
RA   Seemann P., Kunkel D., Zambruno G., Dallapiccola B., Schuelke M.,
RA   Robertson S., Hamamy H., Wollnik B., Van Maldergem L., Mundlos S.,
RA   Kornak U.;
RT   "Mutations in PYCR1 cause cutis laxa with progeroid features.";
RL   Nat. Genet. 41:1016-1021(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-278 AND SER-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF APOENZYME AND IN COMPLEXES
RP   WITH NAD; NADP AND SUBSTRATE ANALOG GLU, CATALYTIC ACTIVITY, FUNCTION,
RP   ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, MUTAGENESIS OF
RP   GLU-221, AND SUBUNIT.
RX   PubMed=16730026; DOI=10.1016/j.jmb.2006.04.053;
RA   Meng Z., Lou Z., Liu Z., Li M., Zhao X., Bartlam M., Rao Z.;
RT   "Crystal structure of human pyrroline-5-carboxylate reductase.";
RL   J. Mol. Biol. 359:1364-1377(2006).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 1-300 IN COMPLEX WITH NAD.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human pyrroline-5-carboxylate reductase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [18]
RP   VARIANT ARCL2B GLN-266.
RX   PubMed=19576563; DOI=10.1016/j.ajhg.2009.06.008;
RA   Guernsey D.L., Jiang H., Evans S.C., Ferguson M., Matsuoka M.,
RA   Nightingale M., Rideout A.L., Provost S., Bedard K., Orr A.,
RA   Dube M.-P., Ludman M., Samuels M.E.;
RT   "Mutation in pyrroline-5-carboxylate reductase 1 gene in families with
RT   cutis laxa type 2.";
RL   Am. J. Hum. Genet. 85:120-129(2009).
RN   [19]
RP   VARIANT ARCL3B GLU-248, AND VARIANT ARG-297.
RX   PubMed=22052856; DOI=10.1002/ajmg.a.34326;
RA   Lin D.S., Chang J.H., Liu H.L., Wei C.H., Yeung C.Y., Ho C.S.,
RA   Shu C.H., Chiang M.F., Chuang C.K., Huang Y.W., Wu T.Y., Jian Y.R.,
RA   Huang Z.D., Lin S.P.;
RT   "Compound heterozygous mutations in PYCR1 further expand the
RT   phenotypic spectrum of De Barsy syndrome.";
RL   Am. J. Med. Genet. A 155:3095-3099(2011).
CC   -!- FUNCTION: Housekeeping enzyme that catalyzes the last step in
CC       proline biosynthesis. Can utilize both NAD and NADP, but has
CC       higher affinity for NAD. Involved in the cellular response to
CC       oxidative stress. {ECO:0000269|PubMed:16730026,
CC       ECO:0000269|PubMed:19648921}.
CC   -!- CATALYTIC ACTIVITY: L-proline + NAD(P)(+) = 1-pyrroline-5-
CC       carboxylate + NAD(P)H. {ECO:0000269|PubMed:16730026}.
CC   -!- ENZYME REGULATION: Subject to competitive inhibition by the
CC       reaction product proline. Subject to competitive inhibition by
CC       stearoyl coenzyme A. {ECO:0000269|PubMed:16730026}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.151 mM for NAD(+) {ECO:0000269|PubMed:16730026};
CC         KM=3.06 mM for NADP(+) {ECO:0000269|PubMed:16730026};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-
CC       proline from L-glutamate 5-semialdehyde: step 1/1.
CC   -!- SUBUNIT: Homodecamer; composed of 5 homodimers.
CC       {ECO:0000269|PubMed:16730026, ECO:0000269|Ref.17}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-848624, EBI-848624;
CC       Q99497:PARK7; NbExp=5; IntAct=EBI-848624, EBI-1164361;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:19648921}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P32322-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P32322-2; Sequence=VSP_044507;
CC       Name=3;
CC         IsoId=P32322-3; Sequence=VSP_054616;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Cutis laxa, autosomal recessive, 2B (ARCL2B)
CC       [MIM:612940]: A disorder characterized by an excessive congenital
CC       skin wrinkling, a large fontanelle with delayed closure, a typical
CC       facial appearance with downslanting palpebral fissures, a general
CC       connective tissue weakness, and varying degrees of growth and
CC       developmental delay and neurological abnormalities. Patients do
CC       not manifest metabolic abnormalities.
CC       {ECO:0000269|PubMed:19576563, ECO:0000269|PubMed:19648921}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Cutis laxa, autosomal recessive, 3B (ARCL3B)
CC       [MIM:614438]: A disorder characterized by an aged appearance with
CC       distinctive facial features, sparse hair, ophthalmologic
CC       abnormalities, intrauterine growth retardation, and cutis laxa.
CC       {ECO:0000269|PubMed:19648921, ECO:0000269|PubMed:22052856}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the pyrroline-5-carboxylate reductase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG17242.1; Type=Frameshift; Positions=214; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Mendelian genes pyrroline-5-carboxylate
CC       reductase 1 (PYCR1); Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/PYCR1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M77836; AAA36407.1; -; mRNA.
DR   EMBL; AF218000; AAG17242.1; ALT_FRAME; mRNA.
DR   EMBL; AK297627; BAG60002.1; -; mRNA.
DR   EMBL; CR541769; CAG46568.1; -; mRNA.
DR   EMBL; AC145207; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89724.1; -; Genomic_DNA.
DR   EMBL; BC001504; AAH01504.1; -; mRNA.
DR   EMBL; BC071842; AAH71842.1; -; mRNA.
DR   CCDS; CCDS11794.1; -. [P32322-2]
DR   CCDS; CCDS11795.1; -. [P32322-1]
DR   CCDS; CCDS62366.1; -. [P32322-3]
DR   PIR; A41770; A41770.
DR   RefSeq; NP_001269209.1; NM_001282280.1. [P32322-1]
DR   RefSeq; NP_001269210.1; NM_001282281.1. [P32322-3]
DR   RefSeq; NP_008838.2; NM_006907.3. [P32322-1]
DR   RefSeq; NP_722546.1; NM_153824.2. [P32322-2]
DR   RefSeq; XP_005256438.1; XM_005256381.2. [P32322-1]
DR   RefSeq; XP_011521885.1; XM_011523583.2. [P32322-1]
DR   RefSeq; XP_011521886.1; XM_011523584.2. [P32322-1]
DR   UniGene; Hs.163451; -.
DR   PDB; 2GER; X-ray; 3.10 A; A/B/C/D/E=1-319.
DR   PDB; 2GR9; X-ray; 3.10 A; A/B/C/D/E=1-275.
DR   PDB; 2GRA; X-ray; 3.10 A; A/B/C/D/E=1-275.
DR   PDB; 2IZZ; X-ray; 1.95 A; A/B/C/D/E=1-300.
DR   PDB; 5UAT; X-ray; 1.92 A; A/B/C/D/E=1-300.
DR   PDB; 5UAU; X-ray; 1.90 A; A/B/C/D/E=1-300.
DR   PDB; 5UAV; X-ray; 1.85 A; A/B/C/D/E=1-300.
DR   PDB; 5UAW; X-ray; 1.85 A; A/B/C/D/E=1-300.
DR   PDB; 5UAX; X-ray; 1.85 A; A/B/C/D/E=1-270.
DR   PDBsum; 2GER; -.
DR   PDBsum; 2GR9; -.
DR   PDBsum; 2GRA; -.
DR   PDBsum; 2IZZ; -.
DR   PDBsum; 5UAT; -.
DR   PDBsum; 5UAU; -.
DR   PDBsum; 5UAV; -.
DR   PDBsum; 5UAW; -.
DR   PDBsum; 5UAX; -.
DR   ProteinModelPortal; P32322; -.
DR   SMR; P32322; -.
DR   BioGrid; 111789; 29.
DR   IntAct; P32322; 21.
DR   STRING; 9606.ENSP00000328858; -.
DR   DrugBank; DB00172; L-Proline.
DR   DrugBank; DB00157; NADH.
DR   iPTMnet; P32322; -.
DR   PhosphoSitePlus; P32322; -.
DR   SwissPalm; P32322; -.
DR   BioMuta; PYCR1; -.
DR   DMDM; 60416434; -.
DR   EPD; P32322; -.
DR   MaxQB; P32322; -.
DR   PaxDb; P32322; -.
DR   PeptideAtlas; P32322; -.
DR   PRIDE; P32322; -.
DR   TopDownProteomics; P32322-1; -. [P32322-1]
DR   DNASU; 5831; -.
DR   Ensembl; ENST00000329875; ENSP00000328858; ENSG00000183010. [P32322-1]
DR   Ensembl; ENST00000337943; ENSP00000336579; ENSG00000183010. [P32322-2]
DR   Ensembl; ENST00000402252; ENSP00000384949; ENSG00000183010. [P32322-3]
DR   Ensembl; ENST00000619204; ENSP00000479793; ENSG00000183010. [P32322-1]
DR   GeneID; 5831; -.
DR   KEGG; hsa:5831; -.
DR   UCSC; uc002kcp.5; human. [P32322-1]
DR   CTD; 5831; -.
DR   DisGeNET; 5831; -.
DR   GeneCards; PYCR1; -.
DR   HGNC; HGNC:9721; PYCR1.
DR   HPA; HPA047660; -.
DR   MalaCards; PYCR1; -.
DR   MIM; 179035; gene.
DR   MIM; 612940; phenotype.
DR   MIM; 614438; phenotype.
DR   neXtProt; NX_P32322; -.
DR   OpenTargets; ENSG00000183010; -.
DR   Orphanet; 357064; Autosomal recessive cutis laxa type 2B.
DR   Orphanet; 2078; Geroderma osteodysplastica.
DR   Orphanet; 293633; PYCR1-related De Barsy syndrome.
DR   PharmGKB; PA34064; -.
DR   eggNOG; KOG3124; Eukaryota.
DR   eggNOG; COG0345; LUCA.
DR   GeneTree; ENSGT00390000007443; -.
DR   HOGENOM; HOG000230247; -.
DR   HOVERGEN; HBG053399; -.
DR   InParanoid; P32322; -.
DR   KO; K00286; -.
DR   OMA; RTFNEHQ; -.
DR   OrthoDB; EOG091G0KMI; -.
DR   PhylomeDB; P32322; -.
DR   BioCyc; MetaCyc:HS06848-MONOMER; -.
DR   BRENDA; 1.5.1.2; 2681.
DR   Reactome; R-HSA-70614; Amino acid synthesis and interconversion (transamination).
DR   SABIO-RK; P32322; -.
DR   UniPathway; UPA00098; UER00361.
DR   EvolutionaryTrace; P32322; -.
DR   GeneWiki; PYCR1; -.
DR   GenomeRNAi; 5831; -.
DR   PRO; PR:P32322; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000183010; -.
DR   CleanEx; HS_PYCR1; -.
DR   ExpressionAtlas; P32322; baseline and differential.
DR   Genevisible; P32322; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004735; F:pyrroline-5-carboxylate reductase activity; IDA:UniProtKB.
DR   GO; GO:0008652; P:cellular amino acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:UniProtKB.
DR   GO; GO:0055129; P:L-proline biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:1903206; P:negative regulation of hydrogen peroxide-induced cell death; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006561; P:proline biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IMP:ParkinsonsUK-UCL.
DR   HAMAP; MF_01925; P5C_reductase; 1.
DR   InterPro; IPR008927; 6-PGluconate_DH_C-like.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR028939; P5C_Rdtase_cat_N.
DR   InterPro; IPR029036; P5CR_dimer.
DR   InterPro; IPR000304; Pyrroline-COOH_reductase.
DR   PANTHER; PTHR11645; PTHR11645; 1.
DR   Pfam; PF03807; F420_oxidored; 1.
DR   Pfam; PF14748; P5CR_dimer; 1.
DR   PIRSF; PIRSF000193; Pyrrol-5-carb_rd; 1.
DR   SUPFAM; SSF48179; SSF48179; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR00112; proC; 1.
DR   PROSITE; PS00521; P5CR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Amino-acid biosynthesis; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Mitochondrion; NADP; Oxidoreductase; Phosphoprotein;
KW   Polymorphism; Proline biosynthesis; Reference proteome;
KW   Stress response.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|Ref.8, ECO:0000269|Ref.9}.
FT   CHAIN         2    319       Pyrroline-5-carboxylate reductase 1,
FT                                mitochondrial.
FT                                /FTId=PRO_0000187314.
FT   NP_BIND       6     11       NADP. {ECO:0000269|Ref.17}.
FT   NP_BIND      69     72       NADP. {ECO:0000269|Ref.17}.
FT   NP_BIND      95     97       NADP. {ECO:0000269|Ref.17}.
FT   BINDING      34     34       NADP; via carbonyl oxygen.
FT                                {ECO:0000269|Ref.17}.
FT   BINDING      56     56       NADP. {ECO:0000269|Ref.17}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000269|Ref.8, ECO:0000269|Ref.9}.
FT   MOD_RES     278    278       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     301    301       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1      1       M -> MVGGGRRVGRDEPVPSVGALGQGSPDSM (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_054616.
FT   VAR_SEQ     290    319       VKLDSPAGTALSPSGHTKLLPRSLAPAGKD -> DHLPLEL
FT                                GSPEGLHPLLLQYQLARAPS (in isoform 2).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_044507.
FT   VARIANT     119    119       R -> G (in ARCL2B; dbSNP:rs121918376).
FT                                {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059068.
FT   VARIANT     119    119       R -> H (in ARCL2B; dbSNP:rs121918377).
FT                                {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059069.
FT   VARIANT     179    179       A -> T (in ARCL2B; dbSNP:rs139751598).
FT                                {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059070.
FT   VARIANT     189    189       A -> V. {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059071.
FT   VARIANT     206    206       G -> R (in ARCL2B; dbSNP:rs121918375).
FT                                {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059072.
FT   VARIANT     206    206       G -> W (in ARCL2B; dbSNP:rs121918375).
FT                                {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059073.
FT   VARIANT     248    248       G -> E (in ARCL3B; results in a reduction
FT                                of protein expression in skin fibroblasts
FT                                from the patient; dbSNP:rs281875319).
FT                                {ECO:0000269|PubMed:22052856}.
FT                                /FTId=VAR_067600.
FT   VARIANT     251    251       R -> H (in ARCL3B; dbSNP:rs121918378).
FT                                {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059074.
FT   VARIANT     257    257       A -> T (in ARCL3B; dbSNP:rs281875318).
FT                                {ECO:0000269|PubMed:19648921}.
FT                                /FTId=VAR_059075.
FT   VARIANT     266    266       R -> Q (in ARCL2B; may cause skipping of
FT                                exon 6; dbSNP:rs121918374).
FT                                {ECO:0000269|PubMed:19576563}.
FT                                /FTId=VAR_059076.
FT   VARIANT     297    297       G -> R. {ECO:0000269|PubMed:22052856}.
FT                                /FTId=VAR_067601.
FT   MUTAGEN     221    221       E->A: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:16730026}.
FT   CONFLICT    155    155       S -> T (in Ref. 1; AAA36407).
FT                                {ECO:0000305}.
FT   CONFLICT    317    317       G -> S (in Ref. 4; CAG46568).
FT                                {ECO:0000305}.
FT   STRAND        3      7       {ECO:0000244|PDB:2IZZ}.
FT   HELIX        10     21       {ECO:0000244|PDB:2IZZ}.
FT   HELIX        27     29       {ECO:0000244|PDB:2IZZ}.
FT   STRAND       30     33       {ECO:0000244|PDB:2IZZ}.
FT   HELIX        40     48       {ECO:0000244|PDB:2IZZ}.
FT   STRAND       51     54       {ECO:0000244|PDB:2IZZ}.
FT   HELIX        56     62       {ECO:0000244|PDB:2IZZ}.
FT   STRAND       64     68       {ECO:0000244|PDB:2IZZ}.
FT   HELIX        72     74       {ECO:0000244|PDB:2IZZ}.
FT   HELIX        75     82       {ECO:0000244|PDB:2IZZ}.
FT   HELIX        83     85       {ECO:0000244|PDB:2IZZ}.
FT   STRAND       91     94       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       101    109       {ECO:0000244|PDB:2IZZ}.
FT   STRAND      112    114       {ECO:0000244|PDB:2GR9}.
FT   STRAND      116    121       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       124    128       {ECO:0000244|PDB:2IZZ}.
FT   STRAND      131    137       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       143    154       {ECO:0000244|PDB:2IZZ}.
FT   STRAND      157    161       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       164    166       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       167    173       {ECO:0000244|PDB:2IZZ}.
FT   TURN        174    176       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       177    194       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       199    219       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       224    231       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       237    247       {ECO:0000244|PDB:2IZZ}.
FT   HELIX       250    270       {ECO:0000244|PDB:2IZZ}.
SQ   SEQUENCE   319 AA;  33361 MW;  9E8C4DED0638EFC5 CRC64;
     MSVGFIGAGQ LAFALAKGFT AAGVLAAHKI MASSPDMDLA TVSALRKMGV KLTPHNKETV
     QHSDVLFLAV KPHIIPFILD EIGADIEDRH IVVSCAAGVT ISSIEKKLSA FRPAPRVIRC
     MTNTPVVVRE GATVYATGTH AQVEDGRLME QLLSSVGFCT EVEEDLIDAV TGLSGSGPAY
     AFTALDALAD GGVKMGLPRR LAVRLGAQAL LGAAKMLLHS EQHPGQLKDN VSSPGGATIH
     ALHVLESGGF RSLLINAVEA SCIRTRELQS MADQEQVSPA AIKKTILDKV KLDSPAGTAL
     SPSGHTKLLP RSLAPAGKD
//
